Start With the Assumption Everyone Accepts
Parkinson's Disease is progressive.
Dopamine neurons degenerate.
Symptoms worsen.
Treatments become less effective over time.
That’s the model.
It’s not wrong.
But it might be incomplete.
What If Part of “Progression” Isn’t Biology… It’s Logistics?
Levodopa still works. That’s not debated.
What fails over time is:
timing
consistency
predictability
Or said plainly:
Delivery breaks down.
The Structural Problem We Built Into the System
Oral levodopa has two unavoidable choke points:
1. The gut
delayed gastric emptying
erratic intestinal absorption
competition with dietary protein
(Nutt & Fellman, Neurology, 1984; Contin & Martinelli, Clin Pharmacokinetics, 2010)
2. The blood-brain barrier
levodopa competes with large neutral amino acids
uses the LNAA transporter
entry into the brain is variable
(Pardridge, NeuroRx, 2005; Fernstrom, Am J Clin Nutr, 2013)
That’s not a small issue.
That’s the entire delivery chain.
Now Add Disease Progression
As Parkinson’s advances:
dopamine storage capacity declines
buffering disappears
the brain depends on real-time plasma levodopa
(Olanow et al., Lancet Neurology, 2006)
So now you have:
A system that requires precision
paired with a delivery method built on variability
And we call what happens next… progression.
Pulsatile Dosing: The Quiet Saboteur
Oral levodopa doesn’t just fluctuate.
It forces the brain to adapt to instability.
Repeated spikes lead to:
receptor sensitization
abnormal basal ganglia signaling
dyskinesias
(Stocchi et al., Movement Disorders, 2010)
We’ve known this for years.
And yet we still treat the most fragile stage of the disease with the most unstable delivery system.
What Changes With Continuous Infusion
Vyalev removes one entire layer of failure:
no gastric timing issues
no intestinal absorption variability
no food interference at the gut level
(AbbVie Prescribing Information, 2024)
Let’s be precise:
It does not bypass the blood-brain barrier.
Levodopa still competes via the LNAA transporter.
But it does something more important:
It stabilizes the signal reaching the brain.
Why That Matters More Than We Admit
In advanced Parkinson’s, the problem isn’t just dopamine deficiency.
It’s dopamine instability.
So when you shift from:
intermittent spikes
to:
continuous exposure
You are not just improving delivery.
You are changing how the brain experiences dopamine.
This aligns with the concept of Continuous Dopaminergic Stimulation, developed specifically to reduce motor complications driven by pulsatile therapy (Olanow et al., 2006).
Here’s Where It Gets Uncomfortable
There are cases, including my own, where:
long-standing Parkinson’s
advanced disease stage
prior DBS
are followed by:
discontinuation of oral meds
DBS turned off
stable function on continuous infusion
That shouldn’t happen.
At least not according to the model.
So you’re left with two options:
1. It’s an anomaly
2. The model is missing something
The Question Nobody Wants to Ask
How much of what we call “progression” is actually:
inconsistent delivery
pharmacokinetic noise
receptor destabilization from years of pulsatile dosing
We assume worsening symptoms reflect worsening disease.
But what if, in part, they reflect:
worsening drug delivery into a system that can no longer compensate?
Be Clear About What This Is NOT Saying
This is not claiming:
Parkinson’s is reversible
dopamine is the only system involved
continuous infusion is a cure
Parkinson’s still affects:
serotonin
norepinephrine
acetylcholine
autonomic function
cognition
Levodopa does not fix that.
What This IS Saying
We may be underestimating the role of delivery architecture in late-stage disease.
Not as a side issue.
As a central one.
Why This Matters Now
Because if delivery matters this much, then:
treatment timing matters
delivery method matters
stability may matter more than dose
And most importantly:
we may be intervening too late with the right strategy
Where This Needs to Go
We need to study:
earlier use of continuous delivery
long-term receptor adaptation under stable dopamine exposure
comparative outcomes of delivery patterns, not just drugs
cases that don’t fit the expected trajectory
Because right now, those cases get ignored.
And they shouldn’t.
Bottom Line
Vyalev doesn’t change the blood-brain barrier.
It changes everything leading up to it.
And in a disease where the brain loses its ability to handle inconsistency, that shift may be more powerful than we’ve been willing to acknowledge.
Final Question
If continuous dopamine delivery can stabilize the system this much…
why are we still relying on a delivery method built on variability to manage the most unstable phase of the disease?
Sources
AbbVie. Vyalev Prescribing Information. 2024
Nutt JG, Fellman JH. Neurology. 1984
Contin M, Martinelli P. Clin Pharmacokinetics. 2010
Pardridge WM. NeuroRx. 2005
Fernstrom JD. Am J Clin Nutr. 2013
Olanow CW et al. Lancet Neurology. 2006
Stocchi F et al. Movement Disorders. 2010
